167 results about "Native protein" patented technology

The invention provides an anti-human thrombopoietin antibody AF687, a kit and application thereof. The anti-human thrombopoietin antibody disclosed by the invention can specifically recognize epitopes without glycosylation modification of natural TPO protein, and has relatively high affinity for recombinant TPO protein and specific epitopes of the recombinant TPO protein. Meanwhile, the anti-human thrombopoietin antibody disclosed by the invention can accurately detect the content of human thrombopoietin in serum, is not influenced by heterogeneity of natural protein glycosylation sites, can be used for accurately identifying and diagnosing early aplastic anemia and primary immune thrombocytopenia, and has the advantages that compared with an existing detection reagent, the anti-human thrombopoietin antibody is high in sensitivity and high in sensitivity. The false positive rate can be reduced from 13.9% to 2.7%, and a more accurate detection method is provided for differential diagnosis of the primary immune thrombocytopenia.

The invention relates to an analysis method for characterizing structures and interaction of non-denatured proteins and compounds thereof based on pulse extreme ultraviolet laser dissociation and mass spectrometry detection. Protein interacts with large and small molecules such as metal ions, drug small molecules, protein, nucleic acid or polysaccharide to form a protein compound. Natural protein and protein compound samples in a biocompatible neutral solution enter a gas phase through a non-denaturing electrospray ionization technology, then radiation excitation is performed on the natural protein and protein compound samples through pulse extreme ultraviolet laser, dissociation is induced to generate protein structure characteristic fragment ions, and finally detection and spectrogram recording are performed on the fragment ions through mass spectrum. According to the invention, the technology for characterizing the structure and interaction of the non-denatured protein and the compound of the non-denatured protein by the extreme ultraviolet band laser is realized for the first time internationally, and the method has the remarkable advantages of high sensitivity, high flux, single amino acid site resolution and the like in the aspect of researching fine structures and conformation dynamic changes of protein-protein and protein-micromolecule interaction interfaces.

The invention relates to the field of biological detection, in particular to a monoclonal antibody combination for detecting human IL-6 protein and application. The combination comprises monoclonal antibodies 3A10 and 2G1, and amino acid sequences of complementary determining regions of variable regions of light and heavy chains of the monoclonal antibodies 3A10 and 2G1 are respectively shown as SEQ ID NO.1-12. The invention defines a complete variable region sequence and a coding nucleotide sequence of the antibody. The combination specifically recognizes human IL-6 recombinant and natural proteins, and has no cross reaction with IL-11. A double-antibody sandwich ELISA kit constructed based on the combination takes 3A10 as a coating antibody and 2G1 as a labeled antibody, and has high sensitivity and high specificity. The problems that an existing reagent is insufficient in specificity and low in sensitivity are solved, a reliable core raw material is provided for IL-6 standardized detection, and the method is suitable for preparation of a kit, a test strip and an antibody chip.

The invention discloses a haemonchus contortus subunit vaccine, and belongs to the field of veterinary vaccines. The subunit vaccine comprises an antigen protein MEP3, an antigen protein AP1, an antigen protein AP8, an antigen protein H11-2, an antigen protein H11-4 and an antigen protein AP5 of galactosylated and modified haemonchus contortus, and the antigen protein MEP3, the antigen protein AP1, the antigen protein AP8, the antigen protein H11-2, the antigen protein H11-4 and the antigen protein AP5 of galactosylated and modified haemonchus contortus. The galactosylation modification of the antigen protein is realized by jointly expressing glycosyl transferase HcGALT of haemonchus contortus and one or more of the proteins in eukaryotic cells. The antigen protein modified by galactosylation in the subunit vaccine is closer to the glycosylation modification of natural protein, and can provide effective immune protection after the goat is infected with haemonchus contortus, and the egg laying rate is reduced by 81.43%. The invention lays a foundation for development of haemonchus contortus subunit vaccines, provides an effective technical means for prevention and treatment of the haemonchus contortus subunit vaccines, and has important application value and popularization prospect.

The invention relates to the technical field of mRNA vaccines, and discloses a feline infectious peritonitis mRNA vaccine as well as a preparation method and application thereof. The feline infectious peritonitis mRNA vaccine comprises mRNA molecules; the mRNA molecule comprises an FIBV-S protein coding sequence as shown in SEQ ID NO: 6. According to the invention, the mRNA sequence for coding the natural FIBV-S protein is modified, so that the FIBV-S protein obtained by translation can be stably maintained at the prefusion conformation and has higher immunogenicity, thereby endowing the mRNA vaccine with a better immune effect and being beneficial to the prevention of feline infectious peritonitis.

The present invention relates to the field of fibers, and in particular, to a preparation method for a protein composite fiber. The preparation method comprises spinning, pretreatment, surface treatment, preparation of modified mineral powder, loading, mixing and crosslinking. A pretreated nascent fiber is immersed in a protein composite solution to be in full contact with modified extract mineral powder and a soluble protein, and a crosslinking reaction is carried out; the structure of the dried fiber is more compact; the extract and the soluble protein are more stable in the fiber while the fiber strength is improved; and the loss rate is less than 1% after washing for 50 times. The protein composite fiber prepared by the present invention is skin-friendly and soft, has good moisture absorption and moisturizing effects, and is rich in amino acid and protein, wherein the content of the protein is up to about 12%. Moreover, in the present invention, a common fiber is used as a base material, thereby achieving natural antibacterial, anti-oxidation and deodorizing effects while endowing fibers such as viscose, acrylic fibers, polyester, chinlon, vinylon, and polypropylene fibers with the advantages of a natural protein on the basis of ensuring excellent properties of the base material itself, and thus the range of application is wider.

The invention discloses a recombinant subunit vaccine for resisting trichomonas pigeonae infection and a preparation method of the recombinant subunit vaccine. The vaccine comprises two recombinant proteins with sequences as shown in SEQ ID NO: 7 and SEQ ID NO: 8 respectively and a pharmaceutically acceptable carrier. According to the invention, Sf9 cells are used for respectively expressing trichomonas pigeonae adhesion protein 33 and adhesion protein 65, the immunogenicity of the obtained recombinant protein is similar to that of natural protein, the expression level is high, the immunogenicity is strong, a very small amount of recombinant protein can provide a better immune protection effect, and the recombinant protein has no pathogenicity to pigeons, and can be used for preparing the recombinant protein for preventing and treating trichomonas pigeonae. Meanwhile, large-scale serum-free suspension culture can be carried out through a bioreactor, so that the vaccine production cost is greatly reduced.

The invention belongs to the technical field of gel dressings, and particularly relates to a bio-based gel dressing for wound treatment and a preparation method thereof.The bio-based gel dressing is prepared from, by weight, 10-17 parts of mussel mucin, 13-20 parts of silk fibroin, 1-5 parts of plant vesicles, 2-4 parts of traditional Chinese medicine polysaccharide, 0.05 part of antibacterial peptide, 1.5 parts of glycerinum and 0.3 part of cross-linking agent; nano plant vesicles which are extracted from a traditional Chinese medicine prescription and have the effect of promoting wound healing are used as a carrier for encapsulating antibacterial peptide, and then the antibacterial peptide is encapsulated in a three-dimensional gel network formed by natural protein, so that controlled release and slow release of antibacterial and anti-inflammatory components are realized, and efficient wound healing is promoted.

The invention discloses composite hydrogel as well as a preparation method and application thereof. The composite hydrogel comprises a hydrogel matrix and a liposome loaded on the hydrogel matrix, the hydrogel matrix comprises a methacrylated natural protein, and the liposome is loaded with a drug; the medicine comprises a medicine for promoting cartilage differentiation and an anti-inflammatory traditional Chinese medicine monomer. According to the invention, through a liposome entrapment technology, the stability and sustained release ability of the insoluble traditional Chinese medicine monomer and the cartilage differentiation induction drug are enhanced. The particle size of the liposome is controllable, the liposome is well combined with a methacrylated natural protein network, a drug sustained release bin can be formed in the hydrogel, long-time and local precise release is achieved, the drug utilization efficiency is improved, and systematic toxic and side effects are avoided.

The invention discloses an anti-soluble transferrin receptor monoclonal antibody as well as a preparation method and application thereof, and belongs to the technical field of antibody detection. According to the antibody, an L101-F760 amino acid sequence of human TfR protein is used as an immunogen, specific screening of B cells, reverse RNA (Ribonucleic Acid) into cDNA (Complementary Deoxyribose Nucleic Acid) through RT-PCR (Reverse Transcription-Polymerase Chain Reaction), then homologous recombination is performed to construct heavy and light chain vectors, and finally multiple rounds of screening are performed to obtain the purified sTfR monoclonal antibody, so that the sTfR protein can be specifically recognized, and the antibody has the advantages of high specificity and high sensitivity and can be widely applied to the field of immunotherapy. The natural sTfR protein in human serum can be recognized. The kit is applied to the detection and screening fields of immunohistochemistry, immunofluorescence chemistry, western blot, co-immunoprecipitation, indirect ELISA, flow cytometry and the like, especially has low background and no interference of non-specific binding impure protein during immunohistochemistry detection, can obtain more accurate detection and evaluation results, avoids interference of false positive and false negative, and has high detection accuracy. The method has great application value in the aspects of basic scientific research and clinical pathology detection.

The invention discloses a method for realizing high-efficiency selenium labeling of protein, which comprises the following steps of: in the process of expressing plasmids containing target protein through a prokaryote expression system, realizing high-efficiency replacement of cysteine sulfur atoms in the target protein by selenium atoms by regulating and controlling the ratio of selenium to sulfur elements in a culture medium; on the premise of keeping a good growth state of cells, the selenium labeling efficiency can reach 86%, and the protein expression quantity is stabilized at about 1mg / g (protein / thallus wet weight); structural analysis shows that the secondary structure of the obtained selenium-labeled protein is basically consistent with that of natural protein and is not obviously changed. The method is easy and convenient to operate, high in labeling efficiency, high in protein yield, good in repeatability and suitable for structural biology research such as nuclear magnetic resonance, an effective means is provided for research of the functional mechanism of sulfur atoms in biomacromolecules (including small peptides, polypeptides, peptide fragments, proteins and protein or peptide complexes) with selenium as a probe, and the method has a wide application prospect. Good scientific research application prospects and industrial popularization values are realized.

The invention relates to the field of preparation of materials for articular cartilage repair, in particular to collagen and chitosan cross-linked temperature-sensitive gel for articular cartilage repair and a preparation method of the collagen and chitosan cross-linked temperature-sensitive gel. The cartilage repair material prepared by the invention adopts the recombinant human collagen with a triple helix structure as a main raw material. The raw material is prepared by using a mammalian cell expression system, is close to protein folding and polymerization of natural protein, and has a spatial structure and modification necessary for active protein. The recombinant human collagen with the triple-helix structure is good in biocompatibility and free of rejection reaction and anaphylactic reaction, and the risk of disease transmission possibly caused by animal-derived collagen can be avoided. The injection type temperature-sensitive gel is liquid at low temperature and is converted into hydrogel at 37 DEG C, so that the injection type temperature-sensitive gel is suitable for being used as a transfer carrier for in-vivo injection treatment, secondary injury of an organism is effectively avoided, and the injection type temperature-sensitive gel has a wide clinical application prospect.

This invention provides a nitrile hydrolase mutant and its application in the synthesis of p-cyanobenzoic acid. The invention provides a nitrile hydrolase mutant that enhances the catalytic activity for the synthesis of p-cyanobenzoic acid. The mutant protein is a non-natural protein, and it exhibits significantly enhanced activity in catalyzing the conversion of terephthalonitrile to p-cyanobenzoic acid. Furthermore, the mutant protein contains mutations in two or more core amino acids related to the enzyme's catalytic activity in the wild-type nitrile hydrolase. The nitrile hydrolase mutant of this invention can significantly improve the yield of the synthesized product catalyzed by the nitrile hydrolase.

The present invention relates to a method for obtaining a genetically modified progeny of an avian animal by packaging a gene edited or genetically modified vector in a recombinant adenovirus and injecting into the dorsal aorta of an embryo when PGCs migrate to a developing gonad; compared with the existing disclosed method for transforming the PGCs in vitro, the operation method disclosed by the invention not only can stably and effectively infect the PGCs in vivo, but also has the advantages that more importantly, the probability of generating gene editing offspring is higher, and particularly, the breeding efficiency of cultivating the transgenic chicken offspring with KRT75L4 gene and MSTN gene knockout is higher; and on the other hand, the reporter gene or crispr-cas protein gene does not need to be integrated into the genome of the bird and the non-native protein does not need to be expressed, so that the operability is higher from the commercial level.

A gene editing protein variant is capable of reducing a gene editing off-target rate. The variant is an unnatural protein with cis-cleavage activity, and the variant has reduced trans-cleavage activity as compared to a wild-type gene editing protein thereof. Furthermore, the variant is mutated at one or more of cleavage activity-related core amino acid sites of the wild-type gene editing protein selected from the following: a phenylalanine (F) site corresponding to the 1081st position of FnCas12a; and / or a lysine (K) site corresponding to the 1069th site of the FnCas12a. The variant can have cis-cleavage activity and reduced trans-cleavage activity. Moreover, the gene editing protein variant or a gene editing system having the gene editing protein variant can significantly reduce the gene editing off-target rate.

The invention discloses an egg yolk polypeptide capable of improving learning cognitive ability and a preparation method and application thereof, and the egg yolk polypeptide capable of improving learning cognitive ability is obtained by combining ultrasonic alkali treatment with alkaline protease enzymolysis and desalting by using an integrated membrane separation technology. According to the preparation method, the compact structure of the yolk can be destroyed through the ultrasonic alkali treatment and the enzymolysis process, the enzymolysis efficiency of the yolk can be improved, a large number of bioactive peptides are released, the bioactive peptide yield of a final product is stabilized to be 60% or above, the molecular weight of the bioactive peptides is intensively distributed to be 180-2000 Da, and the nutrition utilization rate is improved. The egg yolk polypeptide prepared by the method can significantly increase the value-added rate of nerve cells and improve the spatial memory ability and cognitive flexibility of mice, ultrasonic alkali treatment is combined with biological enzymolysis, no organic solvent or strong acid and strong alkali is added, and the production process of natural protein hydrolysate is natural and safe and meets the food-grade safety production standard.

The invention provides an anti-human thrombopoietin antibody AF692, a kit and application of the anti-human thrombopoietin antibody AF692. The anti-human thrombopoietin antibody disclosed by the invention can specifically recognize epitopes without glycosylation modification of natural TPO protein, and has relatively high affinity for recombinant TPO protein and specific epitopes of the recombinant TPO protein. Meanwhile, the anti-human thrombopoietin antibody disclosed by the invention can be used for accurately detecting the content of human thrombopoietin in serum, is not influenced by natural protein glycosylation site heterogeneity, and can be used for accurately identifying and diagnosing early aplastic anemia and primary immune thrombocytopenia; and a more accurate detection method is provided for differential diagnosis of the primary immune thrombocytopenia.

A protein complex model global quality evaluation method based on a deep fusion network belongs to the field of bioinformatics and computer application, and comprises the following steps: firstly, setting specific thresholds for maximum sequence redundancy, resolution and residue length in a protein database RCSB PDB to screen out a natural protein structure; for each protein structure, generating a disturbance structure model by using an HDck and xTrimoMultimer docking algorithm and combining a chain orientation disturbance strategy; then, extracting evolutionary features, physical features and geometric features based on each protein structure model, and constructing a deep fusion network fusing a deep convolutional neural network, an axial attention mechanism network and a graph attention network so as to fully capture local and global topological information of a protein compound; and finally, a global quality score is obtained through prediction of a decoding module. According to the method, the global topological information of the protein complex model can be effectively captured, so that the quality of the protein complex model is evaluated.

The present invention relates to a method for the treatment of a semimanufactured product made of leather or similar material. The method comprises the steps of: - providing the semimanufactured product to be treated; - preparing a treatment solution comprising a binder solution and silver in granules; - applying the treatment solution to at least one surface of said semimanufactured product to be treated. The binder solution comprises natural proteins in aqueous solution. The present invention also relates to an item produced from a semimanufactured product made of leather or similar material treated with the aforesaid method.

The invention provides a high-protein feed raw material and a preparation method thereof, and belongs to the field of protein feeds.The preparation method comprises the steps that animal-derived organs are selected, an animal-derived organ enzyme solution is obtained through a pretreatment means, and natural protein components in the animal-derived organ enzyme solution are reserved to serve as crude protein nutritional ingredients; step 2, adding a substrate and a methyl donor into the animal-derived visceral organ enzyme liquid, and generating guanidinoacetic acid and creatine through an enzymatic synthesis reaction to obtain a mixed liquid; and step 3, carrying out enzyme system inactivation, centrifugal filtration, drying and crushing on the mixed solution to obtain a finished product. According to the invention, guanidinoacetic acid and creatine are synthesized by in-situ catalysis of animal-derived visceral organ natural enzyme systems, and can be naturally fused with protein components, so that the problem of compatibility is avoided, and growth functional factors do not need to be added from an external source; natural enzyme systems of animal livers and kidneys are directly utilized, industrial enzymes do not need to be purchased, and the natural enzyme systems are more adaptive to a raw material system; protein, natural enzyme systems and mineral substances in the raw materials are synchronously utilized, so that one material has multiple purposes.

The invention discloses a human intragastric factor protein polyclonal antibody and a preparation method thereof. The preparation method comprises the steps of artificial antigen design, animal immune optimization and antibody purification and verification. Accurate epitope design is achieved, structural interference of natural GIF is avoided through artificial polypeptide, and the cross reaction rate is lt; 5%; an efficient immune strategy is adopted, so that the immune period is shortened to 8-10 weeks, and the titer is increased by 2-3 times; low-cost production is realized, natural protein is replaced by the synthesized polypeptide, and the cost is reduced by 60%; the specificity is high, the cross reaction is reduced due to the design of the artificial antigen, and verification data supports specific recognition of natural GIF; large-scale production, polypeptide synthesis and a double-stage purification process are adopted, so that the consistency between batches is high (CV is less than or equal to 8%); the application range is wide, and diagnosis, pathological research and treatment monitoring scenes are covered.

The invention discloses a lactoferrin gel carrier, a preparation method thereof and application of the lactoferrin gel carrier in an oral delivery system. The preparation method comprises the following steps: mixing a lactoferrin solution with transglutaminase, and reacting under mild conditions to form a gel network. According to the method, gel which is compact in structure and high in stability is formed through enzyme catalytic crosslinking, the mechanical strength and embedding capacity of the gel are remarkably enhanced, and the method is suitable for embedding multiple active ingredients (such as probiotics, polyphenol and vitamins) sensitive to heat, oxygen or shear force. The obtained gel carrier can effectively isolate oxygen, moisture and adverse processing environments, and the stability of embedded components in processing, storage and transportation is remarkably improved. The carrier can be slowly released in a gastrointestinal tract environment, and active ingredients are prevented from being degraded too early in gastric acid, so that the intestinal absorption rate and the bioavailability of the carrier are improved. The materials used in the invention are natural proteins, are safe and non-toxic, and accord with food and health care product application standards.

The invention relates to the field of cell therapy, in particular to a regulatory T cell targeting IL12RB1 and application of the regulatory T cell. The regulatory T cell provided by the invention comprises a P40 subunit or a mutant thereof. According to the invention, a natural protein sequence is used, so that the risk that the antigen has immunogenicity caused by scFv can be avoided; the Treg cells are homed to the inflammation part, and the activated lymphocytes are inhibited.

The present application belongs to the technical field of bioengineering, and particularly relates to a Claudin18.2 gene engineering antibody based on DNA immunization and a preparation method and application thereof. The Claudin18.2 gene engineering antibody comprises a heavy chain variable region and a light chain variable region; the heavy chain variable region comprises any one of the amino acid sequences shown in SEQ ID NO. 15-16; and the light chain variable region comprises the amino acid sequences shown in SEQ ID NO. 19-20. The Claudin18.2 gene engineering antibody is obtained by immunizing Balb / c mice with full-length plasmid DNA and full-length plasmid DNA+extracellular segment polypeptide as immunogens respectively, obtaining plasma cells capable of secreting specific antibodies against Claudin18.2, and then preparing specific mouse-derived gene engineering antibodies through single-cell optical guidance technology and genetic engineering technology. The gene engineering antibodies have high titer and strong specificity, and have specific recognition ability for natural protein Claudin18.2.

Novel compositions of recombinant human CC10 protein have been generated by chemically modifying the pure protein in vitro. Several new synthetic preparations containing isoforms of chemically modified rhCC10 have been generated by processes that utilize reactive oxygen species and reactive nitrogen species. These preparations contain novel isoforms of rhCC10 which have been characterized with enhanced or altered biological properties compared to the unmodified protein. Preparations containing novel isoforms may be used as standards to identify and characterize naturally occurring isoforms of native CC10 protein from blood or urine and ultimately to measure new CC10-based biomarkers to assess patient disease status. These preparations may also be used to treat respiratory, autoimmune, inflammatory, and other medical conditions that are not effectively treated with the unmodified protein.

The application provides a kind of liposome that can enhance organ targeting, preparation method and application, belongs to the field of biological medicine and nanotechnology.The application first proposes the strategy of actively regulating LNP organ targeting by pre-assembling specific protein crown in vitro, which breaks through the technical limitations of traditional passive formation of natural protein crown.Through selecting main lipids (CDO, CDA, EDM) with different head chemical structures, precise control of protein crown composition is realized.Furthermore, the method of the application is simple in process and mild in condition, only needs standard in vitro incubation steps, and has great clinical transformation potential.The pre-assembled protein crown method provided by the application significantly enhances the organ targeting efficiency of LNP: after pre-incubation of LNP1 with APOA1, the enrichment degree of spleen is increased by 2.8 times;after pre-incubation of LNP2 with VTN, the enrichment degree of lung is increased by 52%;after pre-incubation of LNP3 with APOE, the enrichment degree of liver is increased by 1.2 times.

The present invention pertains to the field of protein engineering, molecular imaging, molecular diagnostics, and biopharmaceutics. Provided herein are six unique Proteimer protein scaffolds (TEX-S2 / S3, TEX-S4, YTHDF3, PUM, DARPin, and Aca2) that demonstrate specificity and affinity comparable to antibodies across a broad range of therapeutic targets. Methods and protocols are provided for generating non-native protein aptamers, Proteimers, which are capable of binding to a diverse set of targets, including RNA, DNA, proteins, post-translational modifications, peptides, small molecules, and prosthetic groups. This platform supports the creation of biotherapeutic aptamers from Proteimer scaffolds for the treatment of various diseases.

The invention provides a continuous fluid extraction method of collagen peptide, and belongs to the technical field of natural protein peptide extraction. The method comprises the following steps: carrying out deliming and / or degreasing treatment on animal raw materials, homogenizing the obtained material, heating, transferring the homogenized material to an enzymolysis tank, adding protease into the enzymolysis tank, adjusting the pH value of the system, carrying out enzymolysis treatment and filtration in sequence, heating the filtered material to a decoloration temperature in the conveying process, and carrying out refined filtration after the decoloration is finished, so as to obtain the collagen peptide. According to the method provided by the invention, the use efficiency of equipment is improved, and the equipment investment is saved; the uniformity of the auxiliary materials is improved in an auxiliary material feeding mode; meanwhile, the collagen peptide powder can be obtained by shortening the whole process time to 4-8 hours, so that the pollution risk is greatly reduced, the product quality is improved, and the purpose of saving the production energy consumption is achieved.

The application provides a method and system capable of end-to-end protein design and analysis verification, and can generate protein or protein complex structure and sequence according to specific requirements, and the method comprises the following steps: performing loss calculation on the three-dimensional structure of the initialized protein sequence obtained through the structure prediction algorithm independently developed by the company based on confidence, stability, target correlation; continuously improving the designed protein sequence and structure based on the Markov chain Monte Carlo algorithm or gradient regression according to the obtained loss; and putting the designed protein structure into a sequence design model to optimize the side chain, and obtaining the optimal candidate protein through screening. The method can train the model to be specific and automatic for protein design, and can generate a new artificial protein which is completely different from natural protein in structure and sequence.

The invention discloses a hydrogel composite scaffold as well as a preparation method and application thereof. The hydrogel composite scaffold comprises a hydrogel matrix and drug-loaded microspheres loaded on the hydrogel matrix, the hydrogel matrix is grafted with a photosensitive group; the drug-loaded microsphere comprises a microsphere matrix and a drug loaded on the microsphere matrix; the hydrogel matrix and the microsphere matrix respectively and independently comprise natural protein and derivatives thereof; the natural protein and the derivative thereof comprise at least one of silk fibroin, sericin, collagen or gelatin. According to the invention, the natural protein and the derivative thereof are grafted and modified by adopting a photosensitive group, so that the injectable property can be realized, and the formed hydrogel matrix has good biological activity, can promote adhesion and proliferation of cells, and is combined with the drug-loaded microspheres to realize controlled release of drugs and promote regeneration and repair of damaged tissues. The hydrogel composite scaffold can be widely applied to preparation of biomedical materials, in particular to preparation of cartilage repair materials.